Skip to main content
SpringerLink
Log in
Book cover

Selective COX-2 Inhibitors pp 127–133Cite as

Specific COX-2 inhibitors: from bench to bedside

  • Chapter

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin have been used to treat various ailments for over 100 years. As a class, these drugs are anti-inflammatory, analgesic and anti-pyretic, and they are widely used to treat chronic inflammatory diseases such as arthritis. The commercially available NSAIDs are approximately equivalent in terms of anti-inflammatory efficacy. All of the NSAIDs, however, also cause adverse effects in a significant fraction of people who consume them, and these side-effects frequently limit therapy. The most common side-effects associated with NSAID therapy are gastrointestinal (GI), with haemorrhage and frank ulceration seen in some patients; these lesions apparently can lead to increased morbidity in long-term NSAID users1. Renal and CNS effects are also observed. Because of these problems, a major goal of the pharmaceutical industry is the development of drugs that possess anti-inflammatory activity but lack the toxic effects associated with current NSAIDs. To date, no NSAIDs with the desired therapeutic profile have been commercially developed.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell R. Gastrointestinal damage associated with the use of non-steroidal anti-inflammatory drugs. New England J Med. 1992; 327: 749–754.

    Article  CAS  Google Scholar 

  2. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirinlike drugs. Nature New Biol. 1971; 231: 232–235.

    PubMed  CAS  Google Scholar 

  3. Smith JB, Willis AL. Aspirin selectively inhibits prostaglandin formation in human platelets. Nature New Biol. 1971; 231: 235–239.

    PubMed  CAS  Google Scholar 

  4. Vane JR, Botting RM. Biological properties of cyclooxygenase products. In: Cunningham FM (ed.) Lipid Mediators. London: Academic Press Ltd, 1994; 61–97.

    Google Scholar 

  5. Portanova J, Zhang Y, Anderson GD et al. Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia and IL-6 production in vivo. J Exp Med. 1996; 184: 883–891.

    Article  PubMed  CAS  Google Scholar 

  6. Morrison AR, Nishikawa KA, Needleman P. Unmasking of thromboxane A2 synthesis by ureteral obstruction in the rabbit kidney. Nature. 1977; 267: 259–260.

    Article  PubMed  CAS  Google Scholar 

  7. Needleman P, Wyche A, Bronson SD, Holmberg S, Morrison AR. J Biol Chem. 1979; 254: 9772–9777.

    PubMed  CAS  Google Scholar 

  8. Raz A, Wyche A, Siegel N, Needleman P. Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and translational phases. Proc Natl Acad Sci USA. 1989; 86: 1657–1661.

    Article  PubMed  CAS  Google Scholar 

  9. Masferrer JL, Seibert K, Zweifel BS, Needleman P. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci USA. 1992; 89: 3917–3921.

    Article  PubMed  CAS  Google Scholar 

  10. Masferrer JL, Zweifel BS, Seibert K, Needleman P. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest. 1990; 86: 1375–1379.

    Article  PubMed  CAS  Google Scholar 

  11. Merlie JP, Fagan D, Mudd J, Needleman P. Isolation and characterization of complementary DNA for sheep seminal vesicle sheep prostaglandin endoperoxide synthase. J Biol Chem. 1988; 263: 3550–3553.

    PubMed  CAS  Google Scholar 

  12. DeWitt D, Smith WL. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA. 1988; 85: 1412–1416.

    Article  PubMed  CAS  Google Scholar 

  13. Yokoyama C, Takai T, Tanabe T. Primary structure of sheep prostaglandin endoperoxide synthase deduced from cDNA sequence. FEBS Lett. 1988; 231: 347–351.

    Article  PubMed  CAS  Google Scholar 

  14. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA. 1991; 88: 2692–2696.

    Article  PubMed  CAS  Google Scholar 

  15. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem. 1991; 266: 12866–12872.

    PubMed  CAS  Google Scholar 

  16. O’Banion MK, Sadowski HB, Winn V, Young DA. A serum-and glucocorticoid regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem. 1991; 266: 23261–23267.

    PubMed  Google Scholar 

  17. Fletcher BS, Kujubu DA, Perrin DM, Herschman HR. Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J Biol Chem. 1992; 267: 4338–4344.

    PubMed  CAS  Google Scholar 

  18. Sirois J, Richards JS. Purification and characterization of a novel, distinct isoform of prostaglandin endoperoxide synthase induced by human chorionic gonadotropin in granulosa cells of rat preovulatory follicles. J Biol Chem. 1992; 267: 6382–6388.

    PubMed  CAS  Google Scholar 

  19. Kujubu DA, Herschman HR. Dexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase/cyclooxygenase gene. J Biol Chem. 1992; 267: 7991–7994.

    PubMed  CAS  Google Scholar 

  20. O’Banion MK, Winn V, Young DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci USA. 1992; 89: 4888–4892.

    Article  PubMed  Google Scholar 

  21. Kujubu DA, Reddy ST, Fletcher BS, Herschman H. Expression of the protein product of the prostaglandin synthase-2/TIS10 gene in mitogen-stimulated Swiss 3T3 cells. J Biol Chem. 1993; 268: 5425–5430.

    PubMed  CAS  Google Scholar 

  22. Picot D, Loll PJ, Garavito RM. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature. 1994; 367: 243–249.

    Article  PubMed  CAS  Google Scholar 

  23. Kurumbail RG, Stevens AM, Gierse JK et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 1996; 384: 644–648.

    Article  PubMed  CAS  Google Scholar 

  24. Gierse J, McDonald J, Hauser S, Rangwala S, Seibert K. A single amino acid difference between cyclooxygenase-1 (COX-1) and-2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J Biol Chem. 1996; 271: 15810–15814.

    Article  PubMed  CAS  Google Scholar 

  25. Futaki N, Arai I, Hamasaki S, Takahashi S, Higuchi S, Otomo S. Selective inhibition of NS-398 on prostanoid production in inflamed tissue in rat carrageenan-air-pouch inflammation. J Pharm Pharmacol. 1992; 45: 753–755.

    Article  Google Scholar 

  26. Futaki N, Yoshikawa K, Yumiko H et al. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effect, which causes minimal stomach lesions. Gen Pharmacol. 1993; 24: 105–110.

    Article  PubMed  CAS  Google Scholar 

  27. Gans KR, Galbraith W, Roman RJ et al. Anti-inflammatory and safety profile of DuP 697; a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther. 1989; 254: 180–187.

    Google Scholar 

  28. Masferrer J, Zweifel B, Manning PT et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and non-ulcerogenic. Proc Natl Acad Sci USA. 1994; 91: 3228–3232.

    Article  PubMed  CAS  Google Scholar 

  29. Seibert K, Zhang Y, Leahy K et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA. 1994; 91: 12013–12017.

    Article  PubMed  CAS  Google Scholar 

  30. Chan C, Boyce S, Brideau C et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: A novel non-steroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharm Exp Ther. 1995; 274: 1531–1537.

    CAS  Google Scholar 

  31. Penning TD, Talley JJ, Bertenshaw SR et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of SC-58635 (celecoxib). J Med Chem. 1997; 40: 1347–1365.

    Article  PubMed  CAS  Google Scholar 

  32. Rome LH, Lands WEM. Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. Proc Natl Acad Sci USA. 1975; 72: 4863–4865.

    Article  PubMed  CAS  Google Scholar 

  33. Copeland RA, Williams JM, Giannaras J et al. Mechanisms of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sci USA. 1994; 91: 11202–11206.

    Article  PubMed  CAS  Google Scholar 

  34. Gierse JK, Hauser SD, Creely DP et al. Expression and selective inhibition of the constitutive and inducible forms of human cyclooxygenase. Biochem J. 1995; 305: 479–484.

    PubMed  CAS  Google Scholar 

  35. Frölich JC. A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. Trends Pharm Sci. 1997; 18: 30–34.

    Article  PubMed  Google Scholar 

  36. Kargman S, Charleson S, Cartwright M et al. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology. 1996; 111:445–454.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. P. Isakson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Zweifel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Masferrer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Koboldt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. Seibert
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. Hubbard
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Geis
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P. Needleman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The William Harvey Research Institute, Saint Bartholomew’s and the Royal London School of Medicine and Dentistry, Charterhouse Square, London, UK

    John Vane  & Jack Botting  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Isakson, P. et al. (1998). Specific COX-2 inhibitors: from bench to bedside. In: Vane, J., Botting, J. (eds) Selective COX-2 Inhibitors. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-4872-6_13

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-4872-6_13

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6041-7

  • Online ISBN: 978-94-011-4872-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation